spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Osteosarcoma 

 HSMN NewsFeed - 26 Apr 2019
Aratana Therapeutics to be Acquired by Elanco Animal Health
Biopharmaceuticals Veterinary Mergers & Acquisitions
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2012
Sagent Pharmaceuticals Announces the Launch of Leucovorin Calcium for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Aug 2012
Spectrum Pharmaceuticals Launches a Broad-based FUSILEV(R) Marketing Campaign; Increases Sales Force Footprint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2011
Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Apr 2011
Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2010
Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV(R) sNDA under Review for Advanced Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2009
Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2009
Takeda to Acquire IDM Pharma, Adding MEPACT(R) (Mifamurtide), the First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Mar 2009
IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Nov 2008
IDM Pharma Receives Recommendation for Approval of Mifamurtide (MEPACT(R), L-MTP-PE) for the Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma in Europe from the Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2008
Spectrum Pharmaceuticals Files Supplemental New Drug Application with FDA for FUSILEV(TM) in Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2008
Lilly Launches New FORTEO Delivery Device
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 15 Aug 2008
Spectrum Pharmaceuticals Launches FUSILEV(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jun 2008
Spectrum Pharmaceuticals Announces FUSILEV(TM) as Tradename for Levoleucovorin for Injection
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
New Drug Application Filing for Levoleucovorin Tablets Completed by Spectrum Pharmaceuticals, Inc.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Mar 2008
FDA Approves New Drug Application (NDA) for LEVOleucovorin, Spectrum's First Proprietary Oncology Drug
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2008
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2008
IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2007
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2007
IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Devices Oncology FDA
 HSMN NewsFeed - 29 May 2007
IDM Pharma Names Timothy P. Walbert as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2007
FDA Advisory Committee Reviews Data on IDM Pharma's Junovan(TM) (mifamurtide) for Treatment of Osteosarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 May 2007
IDM Pharma Appoints Robert De Vaere as Senior Vice President and CFO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Dec 2006
IDM Pharma Announces Acceptance for Review of the NDA for Junovan(TM) (Mifamurtide)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Nov 2006
IDM Pharma Submits Filing for European Market Approval of Mepact(TM) (mifamurtide, Junovan(TM) in the US) in the Treatment of Osteosarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Oct 2006
IDM Pharma Submits New Drug Application to the FDA for Junovan(TM) (mifamurtide) in the Treatment of Osteosarcoma
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 22 additional stories matching:
Osteosarcoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.